Abstract

Methylation patterns in circulating cell-free DNA are potential biomarkers for cancer and other pathologies. Currently, bisulfite treatment underpins most DNA methylation analysis methods, however, it is known to fragment DNA. Circulating DNA is already short, and further fragmentation during bisulfite treatment is of concern, as it would potentially reduce the sensitivity of downstream assays. We used high molecular weight genomic DNA to compare fragmentation and recovery following bisulfite treatment with 2 commercially available kits (Qiagen). The bisulfite treated DNA was visualised on an agarose gel and quantified by qPCR. We also bisulfite treated, visualised and quantitated circulating DNA from plasma. There was no difference in DNA fragmentation between the two kits tested, however, the Epitect Fast kit gave better recovery than the standard Epitect kit, with the same conversion efficiency. We also found that bisulfite treated circulating DNA migrates as distinct bands on agarose gels, suggesting that, in contrast to genomic DNA, it remains largely intact following treatment. Bisulfite treatment of 129 and 234 base PCR products confirmed that this was due to the short length of the circulating DNA fragments. Compared to double stranded DNA, bisulfite treated single stranded DNA gives a very weak signal on gel electrophoresis. DNA fragmentation during bisulfite treatment does not contribute to loss of sensitivity in methylation analysis of circulating DNA. The absence of DNA fragments below approximately 170 bases from agarose gel images of purified circulating DNA raises the possibility that these fragments are single stranded following the DNA extraction step.

Highlights

  • Methylation analysis of circulating cell-free DNA in blood plasma offers scope for the identification of cancer biomarkers[1, 2], as well as determining the tissues types that contribute to the cirDNA pool[3, 4]

  • Bisulfite treatment underpins most DNA methylation analysis methods, it is known to fragment DNA

  • We found that bisulfite treated circulating DNA migrates as distinct bands on agarose gels, suggesting that, in contrast to genomic DNA, it remains largely intact following treatment

Read more

Summary

Introduction

Methylation analysis of circulating cell-free DNA (cirDNA) in blood plasma offers scope for the identification of cancer biomarkers[1, 2], as well as determining the tissues types that contribute to the cirDNA pool[3, 4]. DNA methylation is relevant in the field of cancer diagnostics, since it is more consistent between individual tumours than mutation, and enables PCR detection of tumour DNA without a priori knowledge of the tumour mutation profile[1]. Since it was first described in 1992[5], bisulfite treatment has been the mainstay of DNA methylation analysis. Exploiting DNA methylation for cancer biomarker development has been regarded as a tradeoff between the high consistency of tumour methylation patterns and the decreased assay sensitivity due to fragmentation of DNA targets by bisulfite treatment. Circulating DNA is already short, and further fragmentation during bisulfite treatment is of concern, as it would potentially reduce the sensitivity of downstream assays

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call